Tamoxifen enhances interferon-regulated gene expression in breast cancer cells

Molecular and Cellular Biochemistry

Volumn 167, Issue 1-2, 1997, Pages 169-177

  Lindner, Daniel J ^a   Kolla, Venkatadri ^a   Kalvakolanu, Dhananjaya V ^a,b   Borden, Ernest C ^a,b,c  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Breast cancer; Gene expression; Interferon; Tamoxifen

Indexed keywords

BETA INTERFERON; ESTROGEN RECEPTOR; INTERFERON; RECOMBINANT BETA INTERFERON; TAMOXIFEN; TRANSCRIPTION FACTOR;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG POTENTIATION; GENE; HUMAN; HUMAN CELL; XENOGRAFT;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL DIVISION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON TYPE II; INTERFERON-BETA; INTERFERON-STIMULATED GENE FACTOR 3; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; INTERFERONS; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT PROTEINS; TAMOXIFEN; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0031056416     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006854110122     Document Type: Article

References (40)

1. Kalvakolanu DV, Borden EC: An overview of the interferon system: Signal transduction and mechanisms of action. Cancer Inv 14: 25-53, 1996
2. Darnell JE Jr, Kerr IM, Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994
3. Witt PL, Lindner DJ, D'Cunha J, Borden EC: Pharmacology of interferons: induced proteins, cell activation and antitumor activity. In: BA Chabner and DL Longo (eds). Cancer Chemotherapy and Biotherapy, 2nd edn, Philadelphia: Lippencott-Raven Press, 1996, pp 585-607
4. Goldstein D, Laszlo J: Interferon therapy in cancer: from imaginon to interferon. Cancer Res 46: 4315-4329, 1986
5. Jordan VC, Murphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocrine Rev 11: 578-610, 1990
6. Lippman ME, Bolan G: Oestrogen-responsive human breast cancer in long-term tissue culture. Nature 256: 593-595, 1975
7. Grenman SE, Worsham MJ, Van Dyke DL, England B, McClatchey KD, Babu VR, Roberts JA, Maenpaa J, Carey TE: Establishment and characterization of OM-EC-2, a tamoxifen-sensitive, estrogen receptor-negative human endometrial carcinoma cell line. Gyn Oncol 37: 188-199, 1990
8. Charlier C, Chariot A, Antoine N, Merville MP, Gielen J, Castronovo V: Tamoxifen and its active metabolise inhibit growth of estrogen receptor-negative MDA-MB-435 cells. Biochem Pharmacol 49: 351-358, 1995
9. Croxtall JD, Emmas C, White JO, Choudhary Q, Flower RJ: Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem Pharmacol 47: 197-202, 1994
10. Gibson DEC, Johnson DA, Goldstein D, Langan-Fahey SM, Borden EC, Jordan VC: Human recombinant IFN-beta ser and Tamoxifen: Growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse. Breast Cancer Res and Treat 25: 141-150, 1993
11. Breen B, Leake RE: Steroid Hormones: A Practical Approach. IRL Press, Oxford, 1987, pp 213-214
12. Kanno Y, Kozak CA, Schindler C, Driggers PH, Ennist DL, Gleason SL, Darnell JE Jr, Ozato K: The genomic structure of the murine ICSBP gene reveals the presence of the gamma interferon-responsive element, to which an ISGF3 alpha subunit (or similar) molecule binds. Mol Cell Biol 13: 3951-3963, 1993
13. Bandyopadhyay SK, Leonard GT, Jr., Bandyopadhyay T, Stark GR, Sen GC: Transcriptional induction by double-stranded RNA is mediated by interferon-stimulated response elements without activation of interferon-stimulated gene factor 3. J Biol Chem 270: 19624-19629, 1995
14. Kalvakolanu DV, Bandyopadhyay SK, Harter ML, Sen GC: Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: Block in transcriptional complex formation. Proc Natl Acad Sci USA 88: 7459-7463, 1991
15. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K: Current Protocols in Molecular Biology. Wiley Interscience Publication, New York, NY, 1994
16. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enz Reg 22: 27-55, 1984
17. Kolla V, Lindner DJ, Weihua X, Borden EC, Kalvakolanu DV: Modulation of interferon inducible gene expression by retinoic acid: upregulation of stat 1 protein in IFN-unresponsive cells. J Biol Chem 271: 10508-10514, 1996
18. Gottardis MM, Wagner RJ, Borden EC, Jordan VC: Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res 49: 4765-4769, 1989
19. Sica G, Natoli V, Stella C, Del-Bianco S: Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 60: 2419-2423, 1987
20. Bezwoda WR, Meyer K: Effect of alpha-interferon, 17 beta-estradiol, and tamoxifen on estrogen receptor concentration and cell cycle kinetics of MCF-7 cells. Cancer Res 50: 5387-5391, 1990
21. Van den Berg HW, Leahey WJ, Lynch M, Clarke R, Nelson J: Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects.of tamoxifen. Br J Cancer 55: 255-257, 1987
22. Marth CH, Mayer I, Boch G, Gastl G, Huber C, Flener R, Daxenbichler G: Effects of human interferon alpha-2 and gamma on proliferation, estrogen receptor content, and sensitivity to anti-estrogens of cultured breast cancer cells. In: F Dianzani and GB Lossi (eds). The Interferon System, New York, NY: Raven Press, 1985, pp 367-371
23. Kauppila A, Cantell K, Janne O, Kokko E, Vihko R: Serum sex steroid and peptide hormone concentrations, and endometrial estrogen and progestin receptor levels during administration of human leukocyte interferon. Int J Cancer 29: 291-294, 1982
24. Goldstein D, Bushmeyer SM, Witt PL, Jordan VC, Borden EC: Effects of type I and type II interferons on cultured human breast cells: Interaction with estrogen receptors and with tamoxifen. Cancer Res 49: 2698-2702, 1989
25. Porzsolt F, Otto AM, Trauschel B, Buck C, Wawer AW, Schonenberger H: Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. J Cancer Res Clin Oncol 115: 465-469, 1989
26. Silverman RH: Fascination with 2-5A-dependent RNase: a unique enzyme that functions in interferon action. J Interferon Res 14: 101-104, 1994
27. Katze MG: Regulation of the interferon-induced PKR: can viruses cope? Trends Microbiol 3: 75-78, 1995
28. Ackrill AM, Foster GR, Laxton CD, Flavell DM, Stark GR, Kerr IM: Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1A oncogene. Nucl Acids Res 19: 4387-4393, 1991
29. Gutch MJ, Reich NC: Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene. Proc Natl Acad Sci USA 88: 7913-7917, 1991
30. Foster GR, Ackrill AM, Goldin RD, Kerr IM, Thomas HC, Stark GR: Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA. Proc Natl Acad Sci USA 88: 2888-2892, 1991
31. hopTum-1 Jak kinase causes leukemia-like hematopoietic defects. EMBO J 14: 1412-1420, 1995
32. Wong LH, Krauer K, Hatzinisariou I, Devenish RJ, Ralph SJ: The mechanism of resistance to interferons in melanoma cells: deficiency in signalling at the level of interferon-activated transcription factors. J Interferon and Cytokine Res 15: S172, 1995
33. Matikainen S, Ronni T, Hurme M, Levy DE, Julkunen I: Retinoic acid activates IRF-1 gene expression in promyelocytic NB4 cells and en- hances cellular interferon sensitivity. J Interferon amd Cytokine Res 15: S216, 1995
34. Bandyopadhyay SK, Kumar R, Rubin BY, Sen GC: Interferon-inducible gene expression in HL-60 cells: Effects of the state of differentiation. Cell Growth Diff 3: 369-375, 1992
35. Kalvakolanu DV, Sen GC: Differentiation-dependent activation of interferon-stimulated gene factors and NFκB in mouse embryonal carcinoma cells. Proc Natl Acad Sci USA 90: 3167-3171, 1993
36. Segars JH, Marks MS, Hirschfeld S, Driggers PH, Martinez E, Grippo JE, Brown M, Wahli W, Ozato K: Inhibition of estrogen-responsive gene activation by the retinoid X receptor beta: evidence for multiple inhibitory pathways. Mol Cell Biol 13: 2258-2268, 1993
37. Lonning PE, Hall K, Aakvaag A, Lien EA: Influence of tamoxifen on plasma levels of insulin like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 52: 4719-4723, 1992
38. Butta A, MacLennan K, Flanders KC, Sacks NP, Smith I, McKinna A, Dowsett M, Wakefield LM, Sporn MB, Baum M, Colletta M: Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52: 4261-4264, 1992
39. Kerr DJ, Pragnell IB, Sproul A, Cowan S, Murray T, George D, Leake R: The cytostatic effects of alpha-interferon may be mediated by transforming growth factor-beta. J Mol Endocrinol 2: 131-136, 1989
40. Arkins S, Rebeiz N, Brunke-Reese DL, Biragyn A, Kelley KW: Interferon-gamma inhibits macrophage insulin-like growth factor-I synthesis at the transcriptional level. Mol Endocrinol 9: 350-360, 1995